JAMA:ClinicalTrials.gov网登记多为小型试验

2012-05-06 高晓方译 医学论坛网

  美国学者的一项研究表明,ClinicalTrials.gov网站登记临床试验大多为小型试验,并且在方法学存在显著异质性。论文发表于《美国医学会杂志》[JAMA 2012, 307(17):1838]。   近期报告显示,基于指南的治疗推荐与支持上述推荐的临床试验证据之间存在分歧。研究者从ClinicalTrials.gov网站下载了由96346项临床研究所组成的资料集,并

  美国学者的一项研究表明,ClinicalTrials.gov网站登记临床试验大多为小型试验,并且在方法学存在显著异质性。论文发表于《美国医学会杂志》[JAMA 2012, 307(17):1838]。

  近期报告显示,基于指南的治疗推荐与支持上述推荐的临床试验证据之间存在分歧。研究者从ClinicalTrials.gov网站下载了由96346项临床研究所组成的资料集,并将其输入关系数据库进行合计资料分析。确认干预性试验,并对心血管、精神卫生和肿瘤这3个临床专业进行集中分析。主要转归指标为登记临床试验的报表数据特征、上述特征随时间推移的变化、临床专业的特征差异以及与随机化、设盲和数据监测委员会(DMC)应用相关的因素。

  结果显示,登记的干预临床试验数量从2004~2007年的28881项增多至2007~2010年的40970项,并且数据丢失数出现普遍降低。大部分登记干预试验规模较小,受试者不足100例的占62%。许多临床试验为单中心,并且由机构而非企业或国立卫生研究院(NIH)资助。依据临床专业和资助者不同报告方法存在异质性。企业资助试验的DMC应用少于NIH资助试验;早期与Ⅲ期试验、精神卫生与其他专业试验相比亦存在上述情况。在早期、肿瘤学和器械试验中,随机化和设盲应用较少。

  链接:

  Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056936, encodeId=accf205693625, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Wed Aug 01 03:18:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860943, encodeId=ad9c1860943cd, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 08:18:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952284, encodeId=889e19522849d, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Mon Jun 25 11:18:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507601, encodeId=7527150e60158, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631311, encodeId=d1971631311b5, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-08-01 zhzhxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056936, encodeId=accf205693625, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Wed Aug 01 03:18:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860943, encodeId=ad9c1860943cd, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 08:18:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952284, encodeId=889e19522849d, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Mon Jun 25 11:18:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507601, encodeId=7527150e60158, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631311, encodeId=d1971631311b5, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2013-02-02 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056936, encodeId=accf205693625, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Wed Aug 01 03:18:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860943, encodeId=ad9c1860943cd, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 08:18:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952284, encodeId=889e19522849d, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Mon Jun 25 11:18:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507601, encodeId=7527150e60158, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631311, encodeId=d1971631311b5, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056936, encodeId=accf205693625, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Wed Aug 01 03:18:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860943, encodeId=ad9c1860943cd, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 08:18:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952284, encodeId=889e19522849d, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Mon Jun 25 11:18:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507601, encodeId=7527150e60158, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631311, encodeId=d1971631311b5, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-05-07 zll0628
  5. [GetPortalCommentsPageByObjectIdResponse(id=2056936, encodeId=accf205693625, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Wed Aug 01 03:18:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860943, encodeId=ad9c1860943cd, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 08:18:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952284, encodeId=889e19522849d, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Mon Jun 25 11:18:00 CST 2012, time=2012-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507601, encodeId=7527150e60158, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631311, encodeId=d1971631311b5, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-05-07 feifers

相关资讯

JAMA:ADHD药物不会导致中青年患者心血管风险增高

12月12日,国际著名杂志《美国医学会杂志》The Journal of the American Medical Association刊登了一项基于人群的回顾性队列研究成果“ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults。”,这项研究表明用于治疗注意力缺陷/多动

JAMA:早产与幼儿期和成年早期较高的死亡风险相关

  芝加哥 – 据9月21日刊《美国医学会杂志》上的一则研究披露,在一项包括了对60多万在1973-1979年期间出生的瑞典人所做的研究发现,那些早产的人(即他们的胎龄不到37周者 )与足月产的人相比,他们在其幼童时期及成年早期有着较高的死亡风险。   早产是发达国家围产期(指的是紧靠着出生前后的时期)疾病和死亡的主要原因。 文章的作者写道:“尽管人们已经

JAMA:非高密度脂蛋白胆固醇浓度或与严重心血管事件风险相关

荷兰阿姆斯特丹市学术医学中心研究人员在3月28日出版的《美国医学会杂志》上发表的一项研究成果显示,在他汀类药物治疗的患者中,非高密度脂蛋白胆固醇(非-HDL-C)的浓度似乎与发生某种诸如心肌梗塞或中风等严重心血管事件的风险有关,而低密度脂蛋白胆固醇(LDL-C)和载脂蛋白B的浓度也与严重心血管事件的风险有关。 根据文章的背景资料:“他汀类药物治疗是对心血管疾病进行原发性和继发性预防的药理学治

JAMA:老年人心电图异常与冠心病发病风险相关

       JAMA 4月11日刊发的一份研究报告称,在一般人群中,老年人心电图(ECG)明显或轻微异常均提示8年内出现冠心病(CHD)的风险增加。因此,在风险预测模型中将传统心血管危险因素与ECG异常数据相结合可以提高预测CHD事件的准确度。     美国加州大学旧金山分校的Reto Auer博士及其同事指出,到目前为止,少有研

JAMA:减肥手术或可降低心血管事件的发生

1月4日,JAMA杂志上的一则研究"Bariatric Surgery and Long-term Cardiovascular Events"披露,在肥胖者中,减肥手术与心血管死亡及诸如心肌梗塞和中风事件等的长期发生率的减少有关。 大多数的流行病学研究显示,肥胖症与心血管性事件及死亡的增加有关。根据文章的背景资料:“减肥可能会防止心血管事件的发生,但确凿的证据仍然缺乏。” 瑞典哥德堡大学

JAMA:吃盐适量才健康 并非越少越好

据国外媒体报道,加拿大研究人员近日称,摄入适量食盐,比摄入过多与过少都更健康。该研究很可能助长关于饮食中盐健康效应的辩论。 多年来,医生警告称,大量摄入食盐会增加患高血压及其它心脏疾病的风险,但是最近的研究结果对该论调构成了挑战。 减少食盐摄入量可以降低血压已广为人知,不过并无研究显示,可以就此认为更大范围人群的总体心脏健康水平更高。本月稍早发布的多项研究总结暗示,降低食盐摄入量可能不会提高大